NCT07713121 Maintaining Intraoperative Mean Arterial Pressure at 85 mmHg or Higher to Reduce Postoperative Delirium in Older Patients With Arterial Hypertension Having Non-cardiac Surgery
| NCT ID | NCT07713121 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universitätsklinikum Hamburg-Eppendorf |
| Condition | Postoperative Delirium (POD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 3,432 participants |
| Start Date | 2026-08-21 |
| Primary Completion | 2029-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 3,432 participants in total. It began in 2026-08-21 with a primary completion date of 2029-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
In older patients having surgery, postoperative delirium (an acute disturbance in awareness, attention, or cognition) is common and associated with short-term and long-term morbidity and mortality. The pathophysiology of postoperative delirium is multifactorial - but presumably includes inadequate brain perfusion during surgery caused by low intraoperative blood pressure. Therefore, the investigators aim to determine in a multicenter randomized-controlled trial if targeted intraoperative blood pressure management reduces postoperative delirium. The investigators will test the primary hypothesis that maintaining intraoperative mean arterial pressure at 85 mmHg or higher - compared to at 65 mmHg or higher (routine care) - reduces the incidence of postoperative delirium within the first 3 postoperative days in older patients with arterial hypertension having non-cardiac surgery. The investigators will also assess the duration of postoperative delirium, postoperative complications, and the patients' quality of life. The results of this trial will have a direct impact on guidelines and will help improve medical care for patients and the patients' health. Effective strategies to prevent postoperative delirium are missing. The hypothesis that targeted intraoperative blood pressure management can help reduce postoperative delirium is supported by previous observational studies and interventional trials. This trial is supposed to confirm the causal relationship between intraoperative blood pressure and postoperative delirium and to demonstrate the effectiveness of the therapeutic approach.
Eligibility Criteria
Inclusion Criteria: To be eligible for trial inclusion, patients must: * 1\) be able to provide informed consent, AND * 2\) be ≥65 years old, AND * 3\) be scheduled for elective non-cardiac surgery with general anesthesia that is expected to last ≥120 minutes, AND * 4\) have chronic arterial hypertension requiring antihypertensive medication OR have a systolic arterial pressure ≥140 mmHg or diastolic arterial pressure ≥90 mmHg on a measurement performed within the previous year, AND * 5\) be at high risk for postoperative delirium because: American Society of Anesthesiologists physical status class III or IV OR Charlson Comorbidity Index ≥3 points (please see Appendix 1) OR frailty (documented in medical records or clinical diagnosis) Exclusion Criteria: Patients that meet one or more of the following exclusion criteria cannot participate in the trial: * solid organ transplant surgery * intracranial surgery * surgery in sitting position * sepsis * surgery in the previous 30 days * previous participation in ASPIRE-85
Contact & Investigator
Frequently Asked Questions
Who can join the NCT07713121 clinical trial?
This trial is open to participants of all sexes, aged 65 Years or older, studying Postoperative Delirium (POD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07713121 currently recruiting?
Yes, NCT07713121 is actively recruiting participants. Contact the research team at k.kouz@uke.de for enrollment information.
Where is the NCT07713121 trial being conducted?
This trial is being conducted at Hamburg, Germany.
Who is sponsoring the NCT07713121 clinical trial?
NCT07713121 is sponsored by Universitätsklinikum Hamburg-Eppendorf. The trial plans to enroll 3,432 participants.